These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 31787674)

  • 21. A Novel Boron Lipid to Modify Liposomal Surfaces for Boron Neutron Capture Therapy.
    Shirakawa M; Zaboronok A; Nakai K; Sato Y; Kayaki S; Sakai T; Tsurubuchi T; Yoshida F; Nishiyama T; Suzuki M; Tomida H; Matsumura A
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Boron neutron capture therapy demonstrated in mice bearing EMT6 tumors following selective delivery of boron by rationally designed liposomes.
    Kueffer PJ; Maitz CA; Khan AA; Schuster SA; Shlyakhtina NI; Jalisatgi SS; Brockman JD; Nigg DW; Hawthorne MF
    Proc Natl Acad Sci U S A; 2013 Apr; 110(16):6512-7. PubMed ID: 23536304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asialoglycoprotein receptor targeted micelles containing carborane clusters for effective boron neutron capture therapy of hepatocellular carcinoma.
    Zhang T; Li G; Li S; Wang Z; He D; Wang Y; Zhang J; Li J; Bai Z; Zhang Q; Liu B; Zhao Q; Liu Y; Zhang H
    Colloids Surf B Biointerfaces; 2019 Oct; 182():110397. PubMed ID: 31357127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aggregation of polyethylene glycol polymers suppresses receptor-mediated endocytosis of PEGylated liposomes.
    Shen Z; Ye H; Kröger M; Li Y
    Nanoscale; 2018 Mar; 10(9):4545-4560. PubMed ID: 29461551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of boron nanocapsules for neutron capture therapy.
    Nakamura H; Ueno M; Ban HS; Nakai K; Tsuruta K; Kaneda Y; Matsumura A
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S84-7. PubMed ID: 19406654
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration.
    Abu Lila AS; Nawata K; Shimizu T; Ishida T; Kiwada H
    Int J Pharm; 2013 Nov; 456(1):235-42. PubMed ID: 23928149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of theranostic active-targeting boron-containing gold nanoparticles for boron neutron capture therapy (BNCT).
    Wu CY; Lin JJ; Chang WY; Hsieh CY; Wu CC; Chen HS; Hsu HJ; Yang AS; Hsu MH; Kuo WY
    Colloids Surf B Biointerfaces; 2019 Nov; 183():110387. PubMed ID: 31394419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuated polyethylene glycol immunogenicity and overcoming accelerated blood clearance of a fully PEGylated dendrimer.
    Kojima C; Yao J; Nakajima K; Suzuki M; Tsujimoto A; Kuge Y; Ogawa M; Matsumoto A
    Int J Pharm; 2024 Jun; 659():124193. PubMed ID: 38703934
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
    Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
    Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Receptor-targeted liposomal delivery of boron-containing cholesterol mimics for boron neutron capture therapy (BNCT).
    Thirumamagal BT; Zhao XB; Bandyopadhyaya AK; Naranyanasamy S; Johnsamuel J; Tiwari R; Golightly DW; Patel V; Jehning BT; Backer MV; Barth RF; Lee RJ; Backer JM; Tjarks W
    Bioconjug Chem; 2006; 17(5):1141-50. PubMed ID: 16984121
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liposome formulations of o-carborane for the boron neutron capture therapy of cancer.
    Olusanya TOB; Calabrese G; Fatouros DG; Tsibouklis J; Smith JR
    Biophys Chem; 2019 Apr; 247():25-33. PubMed ID: 30797076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of high boron content liposomes and their promising antitumor effect for neutron capture therapy of cancers.
    Koganei H; Ueno M; Tachikawa S; Tasaki L; Ban HS; Suzuki M; Shiraishi K; Kawano K; Yokoyama M; Maitani Y; Ono K; Nakamura H
    Bioconjug Chem; 2013 Jan; 24(1):124-32. PubMed ID: 23214414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo investigation of boron-rich nanodrugs for treating triple-negative breast cancers via boron neutron capture therapy.
    Lan KW; Huang WY; Chiu YL; Hsu FT; Chien YC; Hsiau YY; Wang TW; Keng PY
    Biomater Adv; 2023 Dec; 155():213699. PubMed ID: 37979440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Boron lipid-based liposomal boron delivery system for neutron capture therapy: recent development and future perspective.
    Nakamura H
    Future Med Chem; 2013 Apr; 5(6):715-30. PubMed ID: 23617433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of pegylation and hapten location at the surface of radiolabelled liposomes on tumour immunotargeting using bispecific antibody.
    Rauscher A; Frindel M; Maurel C; Maillasson M; Le Saëc P; Rajerison H; Gestin JF; Barbet J; Faivre-Chauvet A; Mougin-Degraef M
    Nucl Med Biol; 2014 May; 41 Suppl():e66-74. PubMed ID: 24485990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gold Nanoparticles as Boron Carriers for Boron Neutron Capture Therapy: Synthesis, Radiolabelling and In vivo Evaluation.
    Pulagam KR; Gona KB; Gómez-Vallejo V; Meijer J; Zilberfain C; Estrela-Lopis I; Baz Z; Cossío U; Llop J
    Molecules; 2019 Oct; 24(19):. PubMed ID: 31591329
    [No Abstract]   [Full Text] [Related]  

  • 37. Towards new boron carriers for boron neutron capture therapy: metallacarboranes bearing cobalt, iron and chromium and their cholesterol conjugates.
    Białek-Pietras M; Olejniczak AB; Tachikawa S; Nakamura H; Leśnikowski ZJ
    Bioorg Med Chem; 2013 Mar; 21(5):1136-42. PubMed ID: 23357039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Model studies directed toward the boron neutron-capture therapy of cancer: boron delivery to murine tumors with liposomes.
    Shelly K; Feakes DA; Hawthorne MF; Schmidt PG; Krisch TA; Bauer WF
    Proc Natl Acad Sci U S A; 1992 Oct; 89(19):9039-43. PubMed ID: 1409600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug.
    Xu H; Paxton JW; Wu Z
    Pharm Res; 2015 Jul; 32(7):2428-38. PubMed ID: 25663325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
    Shaji J; Menon I
    Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.